Lite Strategy Inc (LITS)

• Market cap: $25.2M
• 1 day: 0.18%
• 5 days: -3.12%
• 1 month: -40.71%
• 3 months: -35.56%
• 6 months: -56.66%
• Year to date: -51.88%
• 1 year: -67.21%
• 5 years: -98.87%
• 10 years: -97.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Employees: 4